• PCV40 CLINICAL AND ECONOMIC IMPACT OF USE OF A POCKET-SIZED ULTRASOUND DEVICE FOR HEART FAILURE HOSPITALIZATIONS IN ITALY

    Nov 1, 2010, 00:00

  • PMS59 THE EFFECT OF TNF THERAPY, SOCIODEMOGRAPHIC AND CLINICAL FACTORS ON SLEEP DISTURBANCES AND FATIGUE AMONG RHEUMATOID ARTHRITIS-RESULTS FROM THE NDB-PORTUGAL COHORT

    Nov 1, 2010, 00:00

  • PCN36 DRUG UTILIZATION AND PRICE TRENDS OF ORAL-CHEMOTHERAPY MEDICATIONS IN MEDICAID 1991-2008

    Nov 1, 2010, 00:00

  • VA2 GATHERING INFORMATION BY COMPARISON OF DIFFERENT DYNAMIC MODELING APPROACHES FOR EPIDEMIC MODELS

    Nov 1, 2010, 00:00

  • PIN38 AN ECONOMIC EVALUATION OF THE PEDIATRIC VACCINATION SCHEDULE IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • EQ3 ESTIMATING THE SF-6D VALUE SET FOR A POPULATION BASED SAMPLE OF BRAZILIANS

    Nov 1, 2010, 00:00

  • PCN10 ESTIMATION OF THE HEALTH AND COST BURDEN OF HPV-RELATED DISEASES IN THAILAND

    Nov 1, 2010, 00:00

  • PCV36 PRESCRIPTION PATTERN OF DUAL ANTIPLATELET THERAPY AMONG TAIWANESE OLDER ADULTS

    Nov 1, 2010, 00:00

  • ISPOR 4th Asia-Pacific Conference Author Index

    Nov 1, 2010, 00:00

  • MT2 CONDUCTING A MIXED TREATMENT COMPARISON (MTC) IN A SPECIFIC POPULATION- POSTMENOPAUSAL WOMEN WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER WHICH OVEREXPRESSES HER2

    Nov 1, 2010, 00:00

  • PHP116 ANALYSIS OF ANTICOAGULATION BRIDGING THERAPY IN ORTHOPEDIC PATIENTS- REAL WORLD ANALYSIS

    Nov 1, 2010, 00:00

  • PHP5 PATIENT DISCHARGE FROM INTENSIVE CARE UNITS WITHIN AND BETWEEN HOSPITALS IN HUNGARY

    Nov 1, 2010, 00:00

  • PCV15 DIRECT MEDICAL COSTS FOR PULMONARY EMBOLISM AFTER ORTHOPEDIC SURGERY IN SLOVAKIA

    Nov 1, 2010, 00:00

  • PIN18 COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL NEWBORN VACCINATION AGAINST HEPATITIS B VIRUS IN VIETNAM

    Nov 1, 2010, 00:00

  • PHP10 USING ASSET INDEX FOR MEASURING HOUSEHOLD LIVING STANDARDS AND MONITORING HEALTH EQUITY IN THAILAND

    Nov 1, 2010, 00:00

  • PND7 ECONOMIC IMPACT OF PERSISTENCE TO DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PMH1 THE EFFICACY OF DONEPEZIL AND MEMANTINE FOR TREATING BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) IN PATIENTS WITH ALZHEIMERS DISEASE- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PCN107 FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB AND SOCIETAL COST SAVINGS IN SPAIN

    Nov 1, 2010, 00:00

  • PMH10 COST SAVING POTENTIAL OF GENERIC SUBSTITUTION-THE CASE OF ANTIDEPRESSANTS

    Nov 1, 2010, 00:00

  • PDB21 IMPACT ASSESSMENT OF CBIA-DM STRATEGY ON DIABETIC PATIENTS QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PHP57 AN ANALYSIS OF DRUG COST CONTAINMENT POLICY AT A HOSPITAL IN SOUTHERN THAILAND

    Nov 1, 2010, 00:00

  • PCV31 BASELINE HEALTH-RELATED QUALITY OF LIFE STUDY IN HONG KONG CARDIAC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2010, 00:00

  • PHP15 DRUG COMPARATOR DIFFERENCES IN THE THERAPEUTIC BULLETINS IN SPAIN-THE JCNDE EXPERIENCE

    Nov 1, 2010, 00:00

  • PSS28 DEVELOPMENT OF AN INSTRUMENT MIRRORING PATIENT AND PHYSICIAN PERCEPTION OF PSORIASIS SEVERITY AND TREATMENT EFFECT

    Nov 1, 2010, 00:00

  • PDB58 PHARMACOEPIDEMIOLOGICAL ASSAY AND COST-MINIMIZATION ANALYSIS OF ORAL ANTIDIABETIC MEDICATIONS AND INSULINS IN LITHUANIA

    Nov 1, 2010, 00:00

  • CV3 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA

    Nov 1, 2010, 00:00

  • PCN160 THE ROLE OF PATIENT SELECTION CRITERIA IN IDENTIFYING OVARIAN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PCV31 BLOOD PRESSURE CONTROL AND ANTIHYPERTENSIVE STRATEGY DIFFERENCES ACCORDING TO PATIENTS AGE

    Nov 1, 2010, 00:00

  • PSY29 DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA-A HEALTH ECONOMIC EVALUATION

    Nov 1, 2010, 00:00

  • PDB45 COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN

    Nov 1, 2010, 00:00

  • PDB20 A PHARMACOECONOMIC MODEL FOR ADJUVANT TREATMENT IN A SMOKING CESSATION INTERVENTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2010, 00:00

  • DU4 COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE (T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR PATIENTS WITH OPEN ANGLE GLAUC ...

    Nov 1, 2010, 00:00

  • PUK8 BUDGET IMPACT ANALYSIS OF ALISKIRENO IN TYPE 2 DIABETES PATIENTS WITH HYPERTENSION AND NEPHROPATHY IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY

    Nov 1, 2010, 00:00

  • PUK21 LONG-TERM COST-EFFECTIVENESS OF SIROLIMUS BASED REGIMEN COMPARED WITH CALCINEURIN INHIBITOR BASED REGIMENS IN LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS IN KOREA

    Nov 1, 2010, 00:00

  • PIH40 METHODOLOGICAL CONSIDERATIONS WHEN ASSESSING WORK PRODUCTIVITY (WP) AND ACTIVITIES OF DAILY LIVING (ADL) OUTCOMES IN MULTINATIONAL CLINICAL TRIALS IN WOMEN WITH HEAVY AND/OR PROLONGED MENSTRUAL BLEEDING (HPMB) TREATED WITH ESTRADIOL V ...

    Nov 1, 2010, 00:00

  • PIH13 COMPLIANCE WITH HORMONE THERAPY AMONG MENOPAUSAL WOMEN AFTER THE WHI PUBLICATION IN TAIWAN

    Nov 1, 2010, 00:00

  • PMC39 EXAMINING ITEM RESPONSE PATTERNS OVER TIME IN A HEALTH PROFILE MEASURE USING US NATIONAL REPRESENTATIVE SAMPLES- A MULTI-FACET MODEL APPROACH

    Nov 1, 2010, 00:00

  • PIN25 SEASONAL INFLUENZA VACCINATION OF HEALTHY, WORKING-AGE ADULTS- A SYSTEMATIC REVIEW OF ECONOMIC INVESTIGATIONS

    Nov 1, 2010, 00:00

  • PDB61 ECONOMIC EVALUATION OF LIRAGLUTIDE VS. ROSIGLITAZONE OR EXENATIDE FOR TYPE 2 DIABETES MELLITUS IN BULGARIA

    Nov 1, 2010, 00:00

  • PMS76 A LONGITUDINAL COMPARISON OF MAPPING EQUATIONS DERIVED FROM BASELINE AND POST-INTERVENTION DATA

    Nov 1, 2010, 00:00

  • PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2010, 00:00

  • PCV134 THERAPEUTIC VERSUS ACTUAL MARKET SHARES FOR STATINS

    Nov 1, 2010, 00:00

  • ISPOR 13th Annual European Congress Author Index

    Nov 1, 2010, 00:00

  • PCV123 EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK PATIENTS- DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE-TURKISH RESULTS OF EURIKA STUDY

    Nov 1, 2010, 00:00

  • PSY23 COST OF POMPE DISEASE IN POLAND IN 2008 AND 2009

    Nov 1, 2010, 00:00

  • PIH37 RELATIONSHIP BETWEEN HEALTH-CARE PROFESSIONALS ND POPULATION HEALTH STATUS- DO NUMBERS COUNT?

    Nov 1, 2010, 00:00

  • PMS35 COST-EFFECTIVENESS OF TERIPARATIDE IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN SWEDEN

    Nov 1, 2010, 00:00

  • PMH48 IMPACT OF ONCE-DAILY DOSING ON DRUG DISCONTINUATION OF PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PSS9 SUMMARIZING UTILITY VALUES OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION-A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PSS1 EPIDEMIOLOGY AND COMORBIDITIES OF PATIENTS WITH PSORIASIS N TAIWAN

    Nov 1, 2010, 00:00

  • PSY17 ECONOMIC OUTCOMES ASSOCIATED WITH HYDROXYUREA ADHERENCE AMONG PEDIATRIC MEDICAID ENROLLEES WITH SICKLE CELL DISEASE

    Nov 1, 2010, 00:00

  • RS4 THE INFLUENCE OF UK RISK-SHARING MODELS (PATIENT ACCESS SCHEMES) ON PAYERS IN GERMANY AND THE NETHERLANDS. A QUALITATIVE RESEARCH APPROACH

    Nov 1, 2010, 00:00

  • PCN11 GEFITINIB COMPARED WITH DOUBLET CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)- A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

    Nov 1, 2010, 00:00

  • PHP25 DOES HUMAN MEDICINES DEVELOPMENT IN THE EUROPEAN UNION ADDRESS GLOBAL AND REGIONAL HEALTH CONCERNS?

    Nov 1, 2010, 00:00

  • PCV118 TO DETERMINE THE EFFECT OF DIFFERENT DOSES OF POMEGRANATE ON BODY WEIGHT AND BLOOD PRESSURE

    Nov 1, 2010, 00:00

  • PSS14 PHARMACOECONOMICS OF INNOVATIVE MEDICINES FOR TREATMENT OF PSORIASIS IN UKRAINE

    Nov 1, 2010, 00:00

  • PGI9 HOSPITAL COST FOR TREATMENT OF PATIENTS WITH PEPTIC ULCER BLEED (PUB) IN SWEDEN-DATA FROM THE KPP (COST PER PATIENT) DATABASE

    Nov 1, 2010, 00:00

  • PRS46 ADJUSTING FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SEVERITY IN DATABASE RESEARCH- FEASIBILITY OF DEVELOPING AND VALIDATING AN ALGORITHM

    Nov 1, 2010, 00:00

  • PCN150 SYSTEMATIC LITERATURE REVIEW ON THE INTER AND INTRA LABORATORY VARIABILITY OF MOLECULAR TESTING OF RESPONSE TO TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AND THE ASSOCIATED COSTS AND COST-EFFECTIVENESS

    Nov 1, 2010, 00:00

  • PHP20 QUALITY ASSURANCE OF FOURTH HURDLE CONCERNING TO MEDICAL DEVICES

    Nov 1, 2010, 00:00

  • PDB5 TOTAL AND DIABETES-RELATED COSTS ASSOCIATED WITH HYPOGLYCEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS INITIATED ON ORAL ANTIDIABETIC DRUGS FROM A LARGE US MANAGED CARE COHORT

    Nov 1, 2010, 00:00

  • PDB11 CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS- A MODELING ANALYSIS IN THE CHINESE SETTING

    Nov 1, 2010, 00:00

  • PSY30 ONE-YEAR-LONG TREATMENT OF FAILED BACK SURGERY SYNDROME WITH SPINAL CORD STIMULATION- COSTS AND BENEFITS IN THE ITALIAN CONTEXT (PRECISE STUDY)

    Nov 1, 2010, 00:00

  • PIH50 MATERNAL MORTALITY RATE IN INDIA-A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • CN3 QUALITY OF LIFE IN ADVANCED CANCER PATIENT-COMPARISON OF PATIENT-REPORTED OUTCOME (PRO) AND PROXIES ASSESSMENT

    Nov 1, 2010, 00:00

  • PMH17 COST OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN GERMANY

    Nov 1, 2010, 00:00

  • PCV59 COMPLIANCE INFLUENCE, PERSISTENCE AND THE BLOOD PRESSURE CONTROL GRADE ASSOCIATED WITH THE INCIDENCE OF CARDIOVASCULAR EVENTS AND THE SANITARY COSTS IN CONSUMPTION OF FIXED-DOSES IN THE ARTERIAL HYPERTENSION TREATMENT

    Nov 1, 2010, 00:00

  • PGI21 RELATIONSHIP BETWEEN PATIENT PREFERENCES FOR 5-ASA THERAPIES AND SELF-REPORTED ADHERENCE

    Nov 1, 2010, 00:00

  • PMH73 IMPACT OF PLACEBO RUN-IN PERIOD ON RELATIVE TREATMENT EFFECT IN GENERALIZED ANXIETY DISORDER (GAD)

    Nov 1, 2010, 00:00

  • PIN62 AN ECONOMIC EVALUATION OF HIBMENCY VACCINATION FOR THE PREVENTION OF HEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS TYPES C AND Y

    Nov 1, 2010, 00:00

  • PND48 MODIFIED LAST OBSERVATION CARRIED FORWARD IS A SUPERIOR METHOD OF IMPUTATION

    Nov 1, 2010, 00:00

  • PMS1 HIGHER COMORBIDITIES IN PATIENTS WITH GOUT VS. WITHOUT GOUT IN THE US GENERAL POPULATION-THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) 2007-2008

    Nov 1, 2010, 00:00

  • PCV67 COST-EFFECTIVENESS OF FONDAPARINUX VS. ENOXAPARIN IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN RUSSIA

    Nov 1, 2010, 00:00

  • PCV138 MEASUREMENT PROPERTIES OF PEAK VO2 IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PHP100 EVALUATION OF ACCEPTANCE AND REJECTION RATES OF ORPHAN DRUGS ACROSS SIX HTA AGENCIES

    Nov 1, 2010, 00:00

  • PCN78 OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED PRIMARY GASTROINTESTINAL STROMAL TUMOR

    Nov 1, 2010, 00:00

  • PCV30 PREVALENCE AND CONTROL OF TRADITIONAL CARDIOVASCULAR RISK FACTORS AND ANTICIPATED AVOIDABLE CORONARY MORTALITY IN PRIMARY PREVENTION IN EUROPE-THE EURIKA STUDY

    Nov 1, 2010, 00:00

  • PMC6 ESTIMATING EQ-5D TARIFFS FOR MALAYSIA USING TIME TRADE OFF AND VISUAL ANALOGUE SCALE

    Nov 1, 2010, 00:00

  • PMH14 COST ANALYSIS OF ADVERSE EVENTS ASSOCIATED WITH TREATMENT OF BIPOLAR DISORDER- A COMPARISON BETWEEN ARIPIPRAZOLE AND OLANZAPINE IN THE SPANISH HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PHP119 ROLE OF QUALITY IMPROVEMENT FOR MANAGEMENT OF SURGICAL BLEED COMPLICATIONS (SBCS)

    Nov 1, 2010, 00:00

  • PHP1 ORPHAN DRUGS- DOES SOCIETY VALUE RARITY?

    Nov 1, 2010, 00:00

  • PCV21 MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH DIAGNOSTIC AND PROGNOSTIC INFORMATION

    Nov 1, 2010, 00:00

  • PIH3 PARENTERAL ALANYL-GLUTAMMINE IN CRITICALLY ILL PATIENTS- A BAYESIAN META-ANALYSIS OF PUBLISHED TRIALS

    Nov 1, 2010, 00:00

  • PIN72 BRAZILIAN STD/AIDS PROGRAMME- EXPENDITURE ON ANTIRETROVIRAL DRUGS AND EPIDEMIC INDICATORS DURING THE PERIOD 2004-2008

    Nov 1, 2010, 00:00

  • PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL

    Nov 1, 2010, 00:00

  • PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

    Nov 1, 2010, 00:00

  • PIH8 CHANGES IN PELVIC FLOOR MUSCLE FUNCTION DURING THE PERIOPERATIVE PERIOD OF COLPORRHAPHY

    Nov 1, 2010, 00:00

  • PMC58 SYSTEMATIC REVIEW OF STATISTICAL METHODS OF META-ANALYSIS AND INDIRECT COMPARISON POTENTIALLY AVAILABLE TO USE IN SYSTEMATIC REVIEWS-RESULTS FROM THE FIRST PART OF EBAYESMET PROJECT

    Nov 1, 2010, 00:00

  • PCN144 CURRENT CHEMOTHERAPY AND MONOCLONAL ANTIBODY USE PATTERNS IN METASTATIC COLORECTAL CANCER IN WESTERN EUROPE

    Nov 1, 2010, 00:00

  • PRS40 EVALUATION OF SMOKING CESSATION DRUG USE AND OUTCOMES IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PMS5 MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN-MULTI CENTERED COST ANALYSIS

    Nov 1, 2010, 00:00

  • PIN8 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C

    Nov 1, 2010, 00:00

  • PCN5 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT- AN UPDATE OF THE PREVIO ...

    Nov 1, 2010, 00:00

  • PGI12 ECONOMIC CONSEQUENCES OF POORLY CONTROLLED PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE IN GERMANY, ITALY AND SPAIN

    Nov 1, 2010, 00:00

  • PCV132 AN INTERNATIONAL COMPARISON OF ANTIPLATELET USE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE IN UA/NSTEMI AND STEMI PATIENTS UNDERGOING PCI- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)

    Nov 1, 2010, 00:00

  • PCV99 COMPLIANCE AND PERSISTENCE WITH ANTIHYPERTENSIVES IN THE NETHERLANDS; A COMPARATIVE ANALYSIS WITH SPECIFIC FOCUS ON RAAS INTERVENING AGENTS

    Nov 1, 2010, 00:00

  • VA1 ARE THE BENEFITS OF FLU VACCINATION IN THE ELDERLY CORRECTLY SIMULATED IN ECONOMIC ASSESSMENT MODELS?

    Nov 1, 2010, 00:00

  • PMC42 TO WHAT EXTENT CAN TECHNOLOGY IMPROVE THE VALIDITY OF CLINROS?

    Nov 1, 2010, 00:00

  • PIN29 A DYNAMIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN

    Nov 1, 2010, 00:00

  • PHP33 RATIONING IN PRACTICE- EQUITY IN WAITING TIMES FOR ELECTIVE SURGERY IN SWEDEN

    Nov 1, 2010, 00:00

  • PMC28 CLINICIAN REPORTED OUTCOMES- ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION

    Nov 1, 2010, 00:00

  • PMH47 MEDICATION COMPLIANCE AND HEALTH CARE COSTS OF TYPE II DIABETICS WITH SCHIZOPHRENIA NEWLY STARTING HYPOGLYCEMIC THERAPY

    Nov 1, 2010, 00:00

  • PCV125 PROTEIN-C-REACTIVE AS A MARKER OF INFLAMMATION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH SCHIZOPHRENIA-A CROSS-SECTIONAL ANALYSIS OF A HEALTH CARE PROVIDER ADMINISTRATIVE CLAIM DATABASE

    Nov 1, 2010, 00:00

  • PRS1 RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS

    Nov 1, 2010, 00:00

  • PIN47 COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINES IN TAIWAN

    Nov 1, 2010, 00:00

  • PSS17 ECONOMIC EVALUATION OF A 100-WHEY BASED PARTIALLY HYDROLYZED FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG DANISH CHILDREN- PRELIMINARY ANALYSES

    Nov 1, 2010, 00:00

  • PND17 MEMANTINE DELAYS THE ADMISSION OF ALZHEIMERS DISEASE PATIENTS TO NURSING HOME- COST-EFFECTIVENESS ANALYSIS IN FRANCE

    Nov 1, 2010, 00:00

  • PHP21 WHAT ARE THE TOP MOST COSTLY DISEASES FOR USA? THE ALIGNMENT OF BURDEN OF ILLNESS WITH PREVENTION AND SCREENING EXPENDITURES

    Nov 1, 2010, 00:00

  • PGI13 MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B- A COSTEFFECTIVENESS ANALYSIS OF ENTECAVIR (BARACLUDE) IN TURKEY

    Nov 1, 2010, 00:00

  • PSY45 PREGABALIN IS A COST-EFFECTIVE MEDICINE FOR REFRACTORY NEUROPATHIC PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PDB56 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENTS UNDERGOING DIABETIC END-STAGE RENAL DISEASE IN EU AND USA

    Nov 1, 2010, 00:00

  • PHP84 A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING RESTRICTIONS

    Nov 1, 2010, 00:00

  • PIH22 DO LOW-INCOME GROUPS IN PAKISTAN UNDERSTAND THE CONCEPT OF GENERIC MEDICINES?

    Nov 1, 2010, 00:00

  • PIH31 STATIC AND DYNAMIC BALANCE EXAMINATION ON STABILOMETER DURING PREGNANCY

    Nov 1, 2010, 00:00

  • PHP79 REFINING INPATIENT PSYCHIATRIC FACILITY REIMBURSEMENT- LESSONS FROM OTHER MEDICARE PROSPECTIVE PAYMENT SYSTEMS

    Nov 1, 2010, 00:00

  • PCV95 ECONOMIC EVALUATION OF LIFESTYLE INTERVENTION IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN 60-YEAR-OLD MEN IN STOCKHOLM, SWEDEN

    Nov 1, 2010, 00:00

  • PGI10 MODELLING THE IMPACT OF TREATMENT WITH ENTECAVIR ON HEALTH CARE COSTS OF CHRONIC HEPATITIS B IN FRANCE

    Nov 1, 2010, 00:00

  • PDB1 CLINICAL OUTCOMES WITH DPP4 INHIBITORS IN SINGAPORE

    Nov 1, 2010, 00:00

  • PSY41 COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN TWO LA COUNTRIES-COMPARISON WITH THE EUROPEAN EXPERIENCE

    Nov 1, 2010, 00:00

  • PCV25 PATTERN OF LIPID MODIFYING AGENTS PRESCRIPTION AMONG CLUSTERS OF PHYSICIAN IN A THAI TEACHING HOSPITAL, FISCAL YEAR 2009

    Nov 1, 2010, 00:00

  • PCV29 DESIGN OF A DISCRETE CHOICE EXPERIMENT TO QUANTIFY CONSUMER PREFERENCES FOR CHRONIC HEART FAILURE MANAGEMENT PROGRAMS

    Nov 1, 2010, 00:00

  • PCN65 COST-EFFECTIVENESS ANALYSIS OF A FOBT-BASED COLORECTAL CANCER SCREENING PROGRAMME

    Nov 1, 2010, 00:00

  • PCV26 AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OF STAY

    Nov 1, 2010, 00:00

  • PND16 MODELING THE CLINICAL AND ECONOMIC IMPLICATIONS OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE IN GERMANY

    Nov 1, 2010, 00:00

  • PDB63 LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MIELLITUS-ECONOMIC EVALUATION IN ROMANIAN SETTING

    Nov 1, 2010, 00:00

  • PCV37 BURDEN IMPACT OF ATRIAL FIBRILLATION (AF BI) IN RUSSIAN FEDERATION

    Nov 1, 2010, 00:00

  • PCV77 A SIMULATION MODEL TO ASSESS COST-EFFECTIVENESS OF STATINS IN HIGH RISK PATIENTS WITH ELEVATED LDL-C IN SPAIN

    Nov 1, 2010, 00:00

  • PMS36 COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN COSTA RICA

    Nov 1, 2010, 00:00

  • PIH5 MEDICAL COST AND UTILIZATION FOR PATIENTS WITH POSTPARTUM HEMORRHAGE IN KOREA

    Nov 1, 2010, 00:00

  • PMH19 THE BURDEN OF DIAGNOSED, SELF-REPORTED, AND AT-RISK DEPRESSION IN CHINA AND EUROPE

    Nov 1, 2010, 00:00

  • PHP58 ANNUAL HEALTH INSURANCE REIMBURSEMENT OF DENTAL CARE IN HUNGARY

    Nov 1, 2010, 00:00

  • PMH7 FACTORS ASSOCIATED WITH TOTAL TIME AND COST OF PROVIDING CARE FOR THAI PATIENTS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • PHP4 EFFECTIVENESS OF TWO POLICIES TO REDUCE DIPHENOXYLATE CONSUMPTION IN IRAN

    Nov 1, 2010, 00:00

  • PHP106 HTAINSITE-A DATABASE OF NICE SUBMISSIONS AND DECISIONS

    Nov 1, 2010, 00:00

  • PUK7 QUALITY OF LIFE OF MALAYSIAN DIALYSIS PATIENTS ON TRANSPLANT WAITING LIST

    Nov 1, 2010, 00:00

  • PCN1 TOLERABILITY OF FIRST-LINE TREATMENTS OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC)-A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

    Nov 1, 2010, 00:00

  • PMS2 GASTROINTESTINAL AND CARDIOVASCULAR RISK OF NONSELECTIVE NSAIDS AND COX-2 INHIBITORS IN ELDERLY PATIENTS WITH KNEE OSTEOARTHRITIS

    Nov 1, 2010, 00:00

  • PCN39 TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED MELANOMA-A RETROSPECTIVE LONGITUDINAL STUDY

    Nov 1, 2010, 00:00

  • PCV2 ESTIMATION OF ADVERSE EVENTS IN 3 MONTHS AFTER VENOUS THROMBOEMBOLISM EVENT FOR MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY

    Nov 1, 2010, 00:00

  • PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE

    Nov 1, 2010, 00:00

  • PSY19 PREDICTORS OF DULOXETINE TREATMENT INITIATION AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN IN SOUTH CENTER VETERANS AFFAIRS HEALTH CARE NETWORK IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PMC37 DOES DATA COLLECTION FROM ONLINE COMMUNITIES RESULT IN BIASED RESPONSE?

    Nov 1, 2010, 00:00

  • PDB22 COST STUDY OF SELF-MONITORING BLOOD GLUCOSE THROUGH GLUCOMETERS IN PATIENTS WITH DIABETES MELLITUS II IN SPAIN

    Nov 1, 2010, 00:00

  • PMC48 UPDATES AND INNOVATIONS IN ELECTRONIC PATIENT-REPORTED DATA CAPTURE-A REVIEW OF THE EVOLUTION AND FUTURE DIRECTIONS OF EPRO

    Nov 1, 2010, 00:00

  • PDB67 FACTORS INFLUENCING VALUATION OF- AND WILLINGNESS TO PARTICIPATE IN- A LIFESTYLE INTERVENTION- AN EXPLORATORY CONJOINT ANALYSIS WITH DIABETES TYPE 2 PATIENTS

    Nov 1, 2010, 00:00

  • PIH46 A SUBJECTIVE APPROACH TO FACTORS INFLUENCING RECOVERY AMONG MEN WHO ARE ACTIVE IN THE LABOR MARKET

    Nov 1, 2010, 00:00

  • PSS14 WHAT COST OF HLA-B5801 GENOTYPING WOULD BE COST EFECTIVE FOR THE PREVENTION OF ALLOPURINOL-INDUCED STEVENS JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS IN THAILAND- ANALYSES USING A DECISION-ANALYTIC MODEL

    Nov 1, 2010, 00:00

  • PCV85 PRASUGREL VS. CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION- A SPANISH MODEL-BASED COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PCN13 EFFECT OF ZOLEDRONIC ACID AND PAMIDRONATE ON SKELETALRELATED EVENTS AND MORTALITY IN WOMEN WITH BONE METASTASES FROM BREAST CANCER IN A MANAGED CARE PLAN- A RETROSPECTIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PIH6 BUDGET IMPACT ANALYSIS OF INCLUDING LIVER TRANSPLANTATION IN CHILDREN INTO THE UNIVERSAL COVERAGE BENEFIT PACKAGE OF THAILAND

    Nov 1, 2010, 00:00

  • PHP23 HEALTH DECENTRALIZATION, GOVERNMENT HEALTH EXPENDITURE AND HEALTH OUTCOME IN CHINA

    Nov 1, 2010, 00:00

  • PHP90 THE EFFECT OF THE 2007 HOSPITAL REFORM ON THE NUMBER OF PSYCHIATRIC BEDS IN HUNGARY

    Nov 1, 2010, 00:00

  • PMS73 LINKAGE OF ADMINISTRATIVE AND MEDICAL RECORDS DATABASES FOR INVESTIGATING PHARMACEUTICAL USE AND OUTCOMES

    Nov 1, 2010, 00:00

  • PCV56 RENAL MORBIDITY, MORTALITY, AND COSTS IN INDIVIDUALS UNDERGOING INVASIVE CARDIAC CATHETERIZATION PROCEDURES WITH LOW-OSMOLAR CONTRAST MEDIA-A LARGE RETROSPECTIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • VA3 FACTORS INFLUENCING THE DECISION TO BE VACCINATED AGAINST H1N1 IN GREECE

    Nov 1, 2010, 00:00

  • PSS24 QUALITY OF LIFE IN OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • PIH58 HEALTH AND ECONOMY- A GOVERNMENTAL PERSPECTIVE, NATIONAL ACCOUNTING MODEL FOR ASSESSING INVESTMENTS IN ROTAVIRUS VACCINATION

    Nov 1, 2010, 00:00

  • PSY38 COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS FROM THE UK PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PRS42 EFFECTS OF ASTHMA MANAGEMENT, SOCIOECONOMIC STATUS AND MEDICATION INSURANCE CHARACTERISTICS ON EXACERBATION FREQUENCY IN CHILDREN WITH ASTHMA

    Nov 1, 2010, 00:00

  • PCV69 COST-EFFECTIVENESS OF EPLERENONE COMPARED WITH SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2010, 00:00

  • PUK34 PSYCHOMETRIC VALIDATION OF THE SPANISH VERSION OF THE TREATMENT BENEFIT SCALE (TBS) FOR ASSESSING SUBJECTIVE OUTCOMES IN TREATING PATIENTS WITH OVERACTIVE BLADDER

    Nov 1, 2010, 00:00

  • PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2010, 00:00

  • PHP53 COST ANALYSIS OF ANKARA UNIVERSITY SCHOOL OF MEDICINE HOSPITALS

    Nov 1, 2010, 00:00

  • PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE-A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA

    Nov 1, 2010, 00:00

  • PMS8 OCCURRENCE OF SECUNDARY HIP AND FEMUR FRACTURES ACCORDING TO RISK FACTORS FOLLOW-UP 8 YEARS

    Nov 1, 2010, 00:00

  • PGI17 COULD AN INNOVATIVE SURGICAL PROCEDURE SUCH AS STAPLED HEMORRHOIDOPEXY BE COST-EFFECTIVE AND EVEN COST-SAVING IN UK CLINICAL PRACTICE?

    Nov 1, 2010, 00:00

  • HT1 REAL-WORLD DATA-IMPROVING APPROACHES FOR DEMONSTRATING BENEFITS AND RISKS OF NEW DRUGS

    Nov 1, 2010, 00:00

  • PHP30 VANCOMYCIN UTILIZATION EVALUATION IN A TEACHING HOSPITAL BETWEEN FEBRUARY 2007 AND MAY 2008 IN IRAN

    Nov 1, 2010, 00:00

  • PUK3 ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH OVERACTIVE BLADDER (OAB) DISORDER- AN ELECTRONIC MEDICAL RECORD (EMR) DATA ANALYSIS

    Nov 1, 2010, 00:00

  • PND46 NON-LOCAL PATIENT-LEVEL DATA FOR COST-EFFECTIVENESS ADAPTATION TO THE SWEDISH ENVIRONMENT

    Nov 1, 2010, 00:00

  • PHP128 THE USE OF HEALTH PROMOTION INITIATIVES BY MUNICIPALITIES IN BELGIUM. A RETROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI ...

    Nov 1, 2010, 00:00

  • PDB69 UTILITY VALUES FOR DIABETES COMPLICATIONS

    Nov 1, 2010, 00:00

  • MO4 USING AHP WEIGHTS TO FILL MISSING GAPS IN MARKOV DECISION MODELS

    Nov 1, 2010, 00:00

  • PHP3 RARE DISEASES, ORPHAN DRUGS, AND THE LEGISLATION IN CHINA

    Nov 1, 2010, 00:00

  • PCV18 ECONOMIC EVALUATION OF USING HIGH-DOSE ATORVASTATIN FOR THE PREVENTION OF RECURRENT STROKE- EVIDENCE FROM THAILAND

    Nov 1, 2010, 00:00

  • PND26 MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN SCOTLAND AND SPAIN

    Nov 1, 2010, 00:00

  • PSY15 CONSTIPATION RELATED TO OPIOID THERAPY-A COST-OF-ILLNESS AND PREVALENCE DATABASE STUDY IN THE BRAZILIAN PRIVATE SETTING

    Nov 1, 2010, 00:00

  • PMS6 HEALTH-CARE RESOURCE UTILIZATION AND OUTCOMES ANALYSIS OF OSTEOPOROTIC HIP FRACTURES AMONG THAI POST MENOPAUSAL WOMEN-A PILOT INVESTIGATION

    Nov 1, 2010, 00:00

  • PSY33 EARLY STAGE ECONOMIC EVALUATION OF PHARMACOGENOMICBASED DIAGNOSTICS IN CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PIN5 HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE

    Nov 1, 2010, 00:00

  • PIN8 CLINICAL EFFECTIVENESS OF THE SEASONAL INFLUENZA VACCINE IN HEALTHY INDIAN CHILDREN

    Nov 1, 2010, 00:00

  • PMH3 A MULTILEVEL ANALYSIS OF AREA AND INDIVIDUAL EFFECTS ON METHADONE MAINTENANCE TREATMENT IN TAIWAN

    Nov 1, 2010, 00:00

  • PRS17 COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE-A HEALTH CARE ADMINISTRATIVE DATABASES ANALYSIS

    Nov 1, 2010, 00:00

  • PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE- CANADIAN PERSPECTIVE

    Nov 1, 2010, 00:00

  • PUK32 CONTENT VALIDITY OF A PATIENT-REPORTED URINARY URGENCY RATING SCALE- RESULTS OF A COGNITIVE INTERVIEW STUDY

    Nov 1, 2010, 00:00

  • NI2 PATIENT ACCESS SCHEMES IN UK ARE DRIVEN BY HEALTH TECHNOLOGY ASSESMENT

    Nov 1, 2010, 00:00

  • PCV66 ECONOMIC PERFORMANCE OF DABIGATRAN ETEXILATE FOR PRIMARY VTE PREVENTION FOLLOWING TOTAL HIP AND KNEE REPLACEMENT SURGERY IN ITALY

    Nov 1, 2010, 00:00

  • PCV89 COST-EFFECTIVENESS OF DRONEDARONE FOR THE TREATMENT OF ATRIAL FIBRILLATION IN THE UK

    Nov 1, 2010, 00:00

  • PMH5 ESTABLISHING THE COMPARATIVE EFFICACY OF ALZHEIMERS DISEASE THERAPY THROUGH SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS

    Nov 1, 2010, 00:00

  • PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION

    Nov 1, 2010, 00:00

  • PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB

    Nov 1, 2010, 00:00

  • PSY46 INDIRECT COSTS OF MODERATE AND SEVERE FORMS OF PSORIASIS IN CZECH REPUBLIC- CALCULATION BASED ON SELF REPORTED QUESTIONNAIRE

    Nov 1, 2010, 00:00

  • PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) IN ...

    Nov 1, 2010, 00:00

  • PGI4 BUDGET IMPACT ANALYSIS OF ORAL ANTIVIRAL AGENTS FOR THE TREATMENT OF CHRONIC HPATITIS B IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PMH51 HEALTH STATUS AND COST OF CARE IN PATIENTS WITH DEMENTIA IN GERMANY

    Nov 1, 2010, 00:00

  • PDB68 HEALTH RELATED QUALITY OF LIFE (HRQL) AND EQ-5D UTILITIES IN A TYPE 2 DIABETES (T2D) POPULATION- RESULTS FROM A SWEDISH SURVEY

    Nov 1, 2010, 00:00

  • PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PHP111 PREDICTING PREVENTIVE CARE SERVICE UTILIZATION IN A UNITED STATES POPULATION

    Nov 1, 2010, 00:00

  • PDB16 INSULIN GLARGINE IS ASSOCIATED WITH A LOWER INCIDENCE OF DIABETIC FOOT SYNDROME AND MACROVASCULAR COMPLICATIONS COMPARED TO NPH INSULIN IN TYPE 2 DIABETICS UNDER GERMAN REAL-LIFE CONDITIONS

    Nov 1, 2010, 00:00

  • PMH4 A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER-THE EMMY TRIAL

    Nov 1, 2010, 00:00

  • AD1 SHORT MESSAGE SERVICE (SMS)-BASED STRATEGY TO IMPROVE ANTIPSYCHOTIC ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PCN167 INFORMING THE DECISION- IMPROVING GENERALIZABILITY BY PARAMETERIZING RELEVANT INFORMATION IN THE ECONOMIC EVALUATION OF TRASTUZUMAB IN EARLY BREAST CANCER

    Nov 1, 2010, 00:00

  • PIH2 IMPACT OF HPV VACCINATION ON CERVICAL CANCER IN ASIA- RESULTS OF A STATIC MODEL

    Nov 1, 2010, 00:00

  • PCN76 A SIMULATION MODELLING APPROACH TO QUANTIFY THE COST-EFFECTIVENESS OF EXTRA-CORPOREAL PHOTOPHERESIS IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) IN SPAIN

    Nov 1, 2010, 00:00

  • PR4 GLOBAL MARKET ACCESS STRATEGY-AN INTEGRATED APPROACH

    Nov 1, 2010, 00:00

  • PIH18 QUALITY OF LIFE IN THAI WOMEN DIAGNOSED WITH GENITAL WARTS, CERVICAL CANCER, AND CERVICAL INTRAEPITHELIAL NEOPLASIA AT KING CHULALONGKORN MEMORIAL HOSPITAL

    Nov 1, 2010, 00:00

  • PMH46 ADHERENCE RATES OF INJECTABLE VS. ORAL RISPERIDONE FOR PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PRS10 RACE AND ETHNICITY IN EMERGENCY ROOM AND NON-URGENT CARE VISITS AMONG LATINO CHILDREN SUFFERING FROM ASTHMA

    Nov 1, 2010, 00:00

  • PMH15 THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM PATIENTS PERSPECTIVES

    Nov 1, 2010, 00:00

  • PRS12 THE COST ANALYSIS OF BRONCHODILATOR PRESCRIPTIONS FOR TREATMENT OF STABLE COPD IN UKRAINE

    Nov 1, 2010, 00:00

  • PCN19 SYSTEMATIC REVIEW OF ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR EARLY GASTRIC CANCER

    Nov 1, 2010, 00:00

  • PRS14 THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY IN SPAIN

    Nov 1, 2010, 00:00

  • PCN58 SURVEY AND ANALYSIS OF THE COSTS OF METASTATIC COLORECTAL CANCER TREATMENT IN BULGARIA

    Nov 1, 2010, 00:00

  • PCN136 QUALITY OF LIFE AFTER CHEMOTHERAPY IN BREAST CANCER-A STUDY IN SOUTH OF IRAN

    Nov 1, 2010, 00:00

  • PSY66 WEB VERSUS FACE-TO-FACE (FTF) ADMINISTRATION OF A HEALTH UTILITY SURVEY IN THE GENERAL PUBLIC- RESULTS FROM A TIME TRADE-OFF (TTO) SURVEY ON IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

    Nov 1, 2010, 00:00

  • PIH34 CONTENT VALIDITY OF THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX (BII)- RESULTS FROM CONCEPT ELICITATION AND COGNITIVE INTERVIEWS

    Nov 1, 2010, 00:00

  • PMS53 QUALITY OF LIFE, PATIENTS PREFERENCES AND INFORMED DECISION IN TREATING RHEUMATOID ARTHRITIS IN GREECE

    Nov 1, 2010, 00:00

  • PSS11 THE COST-EFFECTIVENESS OF A NEW GEL FORMULATION OF CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE FOR THE TREATMENT OF SCALP PSORIASIS IN NORWAY

    Nov 1, 2010, 00:00

  • PRS9 DRUG UTILIZATION EVALUATION OF COMBINED INHALER THERAPIES AMONG PATIENTS WITH AIRWAY DISEASES IN A 2000-BED MEDICAL CENTER IN TAIWAN

    Nov 1, 2010, 00:00

  • PHP98 COST-EFFECTIVENESS METHODOLOGIES OF STRATEGIES THAT AIM TO CHANGE THE BEHAVIOUR OF HEALTH CARE PROFESSIONALS

    Nov 1, 2010, 00:00

  • PMH26 COST ANALYSIS OF METHADONE MAINTENANCE THERAPY (MMT) PROGRAM IN MALAYSIA

    Nov 1, 2010, 00:00

  • PDB74 TYPE 2 DIABETES PATIENT PERSPECTIVES ON HYPOGLYCEMIA

    Nov 1, 2010, 00:00

  • PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PCN138 HEALTH-CARE COSTS ASSOCIATED WITH BREAST CANCER MANAGEMENT

    Nov 1, 2010, 00:00

  • PMC27 VALUES FOR HEALTH STATES UNDER DIFFERENT LIFE DURATIONS

    Nov 1, 2010, 00:00

  • PHP83 EFFECTS OF COST-CONTAINMENT METHODS TO DRUG PRICE LEVEL IN EUROPE

    Nov 1, 2010, 00:00

  • PMS69 ECONOMY OF NSAIDS IN THE MANAGEMENT OF OSTEOARTHRITIS- SODIUM CHONDROITIN SULFATE VS. CONTROL GROUP

    Nov 1, 2010, 00:00

  • PCV10 ANALYSIS OF INAPPROPRIATE SHOCKS IN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DEVICES

    Nov 1, 2010, 00:00

  • PCV13 CAN WE REDUCE COST OF ILLNESS WITH MORE COMPLIANT PATIENTS? THE ESTIMATION OF EFFECT OF 100 COMPLIANT TO TREATMENTS OF DIABETES AND HYPERTENSION

    Nov 1, 2010, 00:00

  • PSY55 QUALITY OF LIFE OF OVERWEIGHT AND OBESE PATIENTS SEEKING CARE AT A PHARMACEUTICAL CARE SERVICE IN VENEZUELA

    Nov 1, 2010, 00:00

  • PCV14 COSTS OF INITIAL ISCHEMIC STROKE CARE

    Nov 1, 2010, 00:00

  • PMC1 SURVIVAL ANALYSIS WITH COX REGRESSION MODELS-VALIDATING A WEB-BASED CALCULATOR

    Nov 1, 2010, 00:00

  • IR1 METHODS FOR PSYCHOMETRIC AND CLINICAL EVALUATIONS OF CAT-BASED MEASURES OF DISEASE IMPACT IN CHRONIC KIDNEY DISEASE (CKD)

    Nov 1, 2010, 00:00

  • PIN49 COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN FOR TREATING CRONIC HEPATITIS C VIRUS INFECTION COMPARED WITH NO TREATMENT IN MEXICO

    Nov 1, 2010, 00:00

  • HE4 THE EFFECT OF PRICE CONTAINMENT ON THE TREND OF PHARMACEUTICAL EXPENDITURE FROM 1999 TO 2007 IN TAIWAN

    Nov 1, 2010, 00:00

  • PCN61 COST IMPACT OF ORAL CAPECITABINE COMPARED TO 5-FLUOROURACIL FOR TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER

    Nov 1, 2010, 00:00

  • PCN33 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA- A GENERAL POPULATION STUDY

    Nov 1, 2010, 00:00

  • PMH66 PREVALENCE OF AFFECTIVE DISORDERS IN SOUTH-WEST REGION OF SWEDEN

    Nov 1, 2010, 00:00

  • PDB77 QUALITY OF TREATMENT OF DIABETES MELLITUS TYPE 2 IN THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PIH23 A REVIEW OF POSITIVE LIST SYSTEM IN KOREA-ACHIEVEMENTS, CHALLENGES AND SUGGESTIONS

    Nov 1, 2010, 00:00

  • PCN27 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER THE 200-2015 PERIOD IN PORTUGAL

    Nov 1, 2010, 00:00

  • DS1 ESTIMATING ADHERENCE AND PERSISTENCY OF ANTIDEPRESSANTS USING THE KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    Nov 1, 2010, 00:00

  • PMS9 TREND OF HIP FRACTURE INCIDENCE IN BELGIUM BETWEEN 2000 AND 2007 AND FUTURE PROJECTIONS

    Nov 1, 2010, 00:00

  • PMS49 PSYCHOMETRIC PROPERTIES OF THE RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX (RADAI) IN A COMMUNITY POPULATION IN THE US

    Nov 1, 2010, 00:00

  • PMC13 METHODS AND IMPACT OF INCORPORATING MEDICATION COMPLIANCE INTO PHARMACOECONOMIC EVALUATIONS

    Nov 1, 2010, 00:00

  • PIN63 PATIENT PREFERENCES FOR BENEFITS, RISKS, AND WEIGHT OF EVIDENCE ASSOCIATED WITH HEPATITIS B TREATMENTS

    Nov 1, 2010, 00:00

  • PCN38 INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO BIOSIMILARS

    Nov 1, 2010, 00:00

  • PCN11 PREVENTION OF OXALIPLATIN HYPERSENSITIVITY REACTION AND COST SAVING

    Nov 1, 2010, 00:00

  • PUK6 EVALUATION OF PSYCHOMETRIC PROPERTIES OF THE JAPANESE VERSION OF THE NOCTURIA QUALITY OF LIFE QUASTIONNAIRE (N-QOL)

    Nov 1, 2010, 00:00

  • PDB28 THE EFFECT OF METFORMIN BRAND SHIFT BY HOSPITAL ON ANTIDIABETICS UTILIZATION

    Nov 1, 2010, 00:00

  • PGI28 HEALTH-RELATED QUALITY OF LIFE IN OPIOID INDUCED CONSTIPATION PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PHP34 THE EVALUATION OF HEALTH-CARE SYSTEMS OF CHINA, HONG KONG, VIETNAM, THAILAND, MALAYSIA, SINGAPORE AND AUSTRALIA

    Nov 1, 2010, 00:00

  • PMC38 A COGNITIVE DEBRIEFING METHODOLOGY FOR ESTABLISHING EQUIVALENCE DURING E-PRO MIGRATION

    Nov 1, 2010, 00:00

  • PCN129 A DATABASE REVIEW OF PATIENT-REPORTED OUTCOME STUDIES IN EORTC CANCER CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PHP54 BUDGET IMPACT OF ORPHAN DRUGS IN DENMARK COMPARED TO OTHER EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PSS35 COST COMPARISON OF PATIENTS WITH CHRONIC HAND ECZEMA COVERED BY STATUTORY VS. OCCUPATIONAL HEALTH INSURANCES IN GERMANY

    Nov 1, 2010, 00:00

  • PDB83 TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2010, 00:00

  • PDB29 COST OF DIABETES MELLITUS TYPE 1 AND 2 STUDIES IN COUNTRIES OF CENTRAL AND EASTERN EUROPE-A SYSTEMATIC REVIEW OF THE LITARATURE

    Nov 1, 2010, 00:00

  • PIH26 MEDICATION CHECKUPS BY COMMUNITY PHARMACISTS- EXPERIENCE OF 'BROWN-BAG' REVIEWS IN JAPAN

    Nov 1, 2010, 00:00

  • PSS25 MAPPING THE IMPACT OF DRY EYE ON EVERYDAY LIFE (IDEEL) QUESTIONNAIRE TO A PREFERENCE BASED UTILITY INDEX

    Nov 1, 2010, 00:00

  • NI3 NICES COST-EFFECTIVENESS THRESHOLD REVISITED- NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS

    Nov 1, 2010, 00:00

  • PSS2 COMPARISON OF COSTING METHODS- COST TO CHARGE RATIO AND DIAGNOSIS RELATED GROUP USING STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS AS A CASE STUDY

    Nov 1, 2010, 00:00

  • PDB25 RELATIONSHIPS OF QUALITY OF LIFE AND COSTS WITH CLINICAL CHARACTERISTICS OF DIABETES PATIENTS

    Nov 1, 2010, 00:00

  • PIN22 A NOVEL APPROACH FOR ESTIMATING THE VALUE OF ENTECAVIR THERAPY FOR NUCLEOSIDE-NAVE CHRONIC HEPATITIS B PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PSY57 WILLINGNESS TO PAY FOR OBESITY PHARMACOLOGY

    Nov 1, 2010, 00:00

  • PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB

    Nov 1, 2010, 00:00

  • PSY63 WORK AND DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH DIGITAL ULCERS (DUS)-RESULTS FROM THE DUO REGISTRY

    Nov 1, 2010, 00:00

  • PIN3 SURGICAL SITE INFECTION IN AUSTRALIA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PCN54 HOSPITAL UNDERTAKING OF PATIENTS WITH A RESECTION OF LUNG TUMOR IN FRANCE

    Nov 1, 2010, 00:00

  • CE3 COST-UTILITY ANALYSIS OF CHOLINESTERASE INHIBITORS IN THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE

    Nov 1, 2010, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF A FOBT-BASED COLORECTAL CANCER SCREENING PROGRAM

    Nov 1, 2010, 00:00

  • PCN49 PREDICTORS OF THE DIRECT COSTS OF BREAST CANCER IN THE UNITED STATES ELDERLY POPULATION

    Nov 1, 2010, 00:00

  • PDB47 THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING IN TYPE 1 DIABETES PATIENTS IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PIH21 QUALITY OF LIFE IMPACT IN PARENTS CARING FOR SEVERE GASTROENTERITIS IN CHILDREN IN SEVEN COUNTRIES WORLDWIDE

    Nov 1, 2010, 00:00

  • PUK28 THE ECONOMIC BURDEN OF POST-TRANSPLANT EVENTS IN RENAL TRANSPLANT PATIENTS (PORTRAIT STUDY) IN A SINGLE UK CENTRE

    Nov 1, 2010, 00:00

  • PMC54 TREATMENT SATISFACTION INSTRUMENTS FOR DIFFERENT PURPOSES DURING A PRODUCTS LIFECYCLE-KEEPING THE END IN MIND

    Nov 1, 2010, 00:00

  • PCV40 WHICH STRATEGY CAN CONTROL THE EXPENDITURE OF HIGH-PRICE DRUGS?

    Nov 1, 2010, 00:00

  • PHP91 REGIONAL DIFFERENCES IN NUMBER OF PSYCHIATRIC BEDS IN HUNGARY FOLLOWING THE 2007 HEALTH CARE REFORM IN HUNGARY

    Nov 1, 2010, 00:00

  • PCV86 ECONOMIC EVALUATION OF DRONEDARONE IN TREATMENT OF ATRIAL FIBRILLATION IN GREECE

    Nov 1, 2010, 00:00

  • PSY35 THE COST-EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PRS3 COMORBIDITY PROFILING OF COPD PATIENTS IN THE UNITED KINGDOM PRIMARY CARE USING AN INCIDENCE BASED APPROACH TO DETECT ASSOCIATIONS WITH THE DISEASE

    Nov 1, 2010, 00:00

  • PIN10 A SYSTEMATIC REVIEW OF THE ATTRIBUTION OF HUMAN PAPILLOMAVIRUS TYPES AMONG CERVICAL INTRAEPITHELIAL NEOPLASIA AND CERVICAL CANCERS IN JAPAN BY SAMPLING METHODS

    Nov 1, 2010, 00:00

  • PSY39 REAL-WORLD COST-EFFECTIVENESS OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PIH33 COMMUNITY PHARMACIST PERCEPTION TOWARD THEIR ROLE IN HEALTH-CARE SYSTEM OF PAKISTAN- A QUANTITATIVE ASSESSMENT

    Nov 1, 2010, 00:00

  • PUK14 HEALTH CARE COST OF RENAL REPLACEMENT THERAPY IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN15 COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2010, 00:00

  • PHP67 HAS THE QUALITY AND OUTCOMES FRAMEWORK INFLUENCED PRIMARY CARE DATA RECORDING?

    Nov 1, 2010, 00:00

  • PDB55 COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A BASAL-BOLUS REGIMEN IN GERMANY

    Nov 1, 2010, 00:00

  • IN1 ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES AND ACUTE OTITIS MEDIA IN TAIWAN- A NATIONWIDE POPULATION-BASED DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PCN105 COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Nov 1, 2010, 00:00

  • PCN30 ESTIMATING WOMENS PREFERENCES FOR CERVICAL CANCER SCREENING PROGRAMS USING CONJOINT ANALYSIS

    Nov 1, 2010, 00:00

  • PDB9 LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 DIABETES PROJECTED USING THE CORE DIABETES MODEL

    Nov 1, 2010, 00:00

  • PMS4 BURDEN OF DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA- RESULTS FROM 2009 NATIONAL HEALTH AND WELLNESS SURVEY

    Nov 1, 2010, 00:00

  • PSS3 THE ECONOMIC BURDENS FOR PATIENTS WITH PSORIASIS IN TAIWAN

    Nov 1, 2010, 00:00

  • PHP70 CURRENT TRENDS IN HEALTH TECHNOLOGY INCORPORATION (HTI) IN BRAZIL- INSIDE THE NATIONAL HEALTH SYSTEMS (NHS) BLACK BOX

    Nov 1, 2010, 00:00

  • PCN35 PRIMARY HEPATOCELLULAR CARCINOMA PATIENTS REPEATED MEDICAL UTILIZATION AND EXPENDITURE FOR CONFIRMATION IN TAIWAN

    Nov 1, 2010, 00:00

  • A Multimarker Approach for the Prediction of Coronary Artery Disease- Cost-Effectiveness Analysis

    Sep 1, 2010, 00:00

  • Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis

    Sep 1, 2010, 00:00

  • Medical Services Utilization and Expenditure of Obesity-Related Disorders in Taiwanese Adults

    Sep 1, 2010, 00:00

  • Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

    Sep 1, 2010, 00:00

  • Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation across Jurisdictions

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of Therapeutic Hypothermia to Treat Neonatal Encephalopathy

    Sep 1, 2010, 00:00

  • The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications- A Propensity Score-Weighted Difference in Difference Evaluation

    Sep 1, 2010, 00:00

  • An Ounce of Prevention Is Worth a Pound of Cure- A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research

    Sep 1, 2010, 00:00

  • Differences in Child versus Parent Reports of the Child's Health-Related Quality of Life in Children with Epilepsy and Healthy Siblings

    Sep 1, 2010, 00:00

  • A Competing Risks Prescription Refill Model of Compliance and Persistence

    Sep 1, 2010, 00:00

  • Clustering Rasch Results- A Novel Method for Developing Rheumatoid Arthritis States for Use in Valuation Studies

    Sep 1, 2010, 00:00

  • Evaluating Willingness-to-Pay Thresholds for Dementia Caregiving Interventions- Application to the Tailored Activity Program

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

    Sep 1, 2010, 00:00

  • Willingness to Pay for Lung Cancer Treatment

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation- Arguments for a National Approach

    Sep 1, 2010, 00:00

  • The Unit Costs of Inpatient Hospital Days, Outpatient Visits, and Daycare Treatments in the Fields of Oncology and Hematology

    Sep 1, 2010, 00:00

  • Measuring Patient Anxiety in Primary Care- Rasch Analysis of the 6-item Spielberger State Anxiety Scale

    Sep 1, 2010, 00:00

  • How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

    Sep 1, 2010, 00:00

  • The Cost-Effectiveness of Spinal Cord Stimulation for Complex Regional Pain Syndrome

    Sep 1, 2010, 00:00

  • Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom- Findings from the INFORCE Study

    Sep 1, 2010, 00:00

  • Modeling the Long-Term Cost-Effectiveness of the Caries Management System in an Australian Population

    Sep 1, 2010, 00:00

  • The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications

    Sep 1, 2010, 00:00

  • A Cost-Utility Analysis of Microwave Endometrial Ablation versus Thermal Balloon Endometrial Ablation

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Duloxetine- The Stress Urinary Incontinence Treatment (SUIT) Study

    Jul 1, 2010, 00:00

  • A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

    Jul 1, 2010, 00:00

  • General Population Reference Values for the French Version of the EuroQol EQ-5D Health Utility Instrument

    Jul 1, 2010, 00:00

  • Early-Stage Valuation of Medical Devices- The Role of Developmental Uncertainty

    Jul 1, 2010, 00:00

  • Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patients

    Jul 1, 2010, 00:00

  • Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients

    Jul 1, 2010, 00:00

  • Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis

    Jul 1, 2010, 00:00

  • Empirically Evaluating Decision-Analytic Models

    Jul 1, 2010, 00:00

  • Evaluating Interventions to Improve Antiretroviral Adherence- How Much of an Effect Is Required for Favorable Value?

    Jul 1, 2010, 00:00

  • Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer

    Jul 1, 2010, 00:00

  • The Cost-Effectiveness of Group Cognitive Behavioral Therapy Compared with Routine Primary Care for Women with Postnatal Depression in the UK

    Jul 1, 2010, 00:00

  • Populating an Economic Model with Health State Utility Values- Moving toward Better Practice

    Jul 1, 2010, 00:00

  • Abolition of Prescription Copayments in Wales- An Observational Study on Dispensing Rates

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China- A Markov Analysis

    Jul 1, 2010, 00:00

  • Assessing the Economic Value of Public Health Programs Based on Risk- The Case of the Cancer Plan in France

    Jul 1, 2010, 00:00

  • Eliciting Distributions to Populate Decision Analytic Models

    Jul 1, 2010, 00:00

  • A Valuation of Infusion Therapy to Preserve Islet Function in Type 1 Diabetes

    Jul 1, 2010, 00:00

  • The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines

    Jul 1, 2010, 00:00

  • Cost–Utility Analysis of Topical Intranasal Steroids for Otitis Media with Effusion Based on Evidence from the GNOME Trial

    Jul 1, 2010, 00:00

  • Consequences of Screening in Lung Cancer- Development and Dimensionality of a Questionnaire

    Jul 1, 2010, 00:00

  • A Portuguese Value Set for the SF-6D

    Jul 1, 2010, 00:00

  • Incorporating Equity–Efficiency Interactions in Cost-Effectiveness Analysis—Three Approaches Applied to Breast Cancer Control

    Jul 1, 2010, 00:00

  • Network Meta-Analysis- Importance of Appropriate Trial Selection

    Jul 1, 2010, 00:00

  • Response to Comments on “No Study Left Behind- A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”

    Jul 1, 2010, 00:00

  • Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation

    Jun 1, 2010, 00:00

  • Net Clinical Benefit- The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment

    Jun 1, 2010, 00:00

  • Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

    Jun 1, 2010, 00:00

  • Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1- Are Tobit and CLAD Models Appropriate?

    Jun 1, 2010, 00:00

  • An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

    Jun 1, 2010, 00:00

  • Patient Expectations and Health-Related Quality of Life Outcomes Following Total Joint Replacement

    Jun 1, 2010, 00:00

  • Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries

    Jun 1, 2010, 00:00

  • Cost–Effectiveness of Osteoporosis Screening Followed by Treatment- The Impact of Medication Adherence

    Jun 1, 2010, 00:00

  • International Development of the Unidimensional Fatigue Impact Scale (U-FIS)

    Jun 1, 2010, 00:00

  • Experimental and Observational Data and Formulary Listing

    Jun 1, 2010, 00:00

  • Social Time Preferences for Health and Money Elicited with a Choice Experiment

    Jun 1, 2010, 00:00

  • Bayesian Analysis of Nosocomial Infection Risk and Length of Stay in a Department of General and Digestive Surgery

    Jun 1, 2010, 00:00

  • Distributions of Parameters for Uncertainty Analysis Cannot Be Defined without Using Prior Information

    Jun 1, 2010, 00:00

  • Health Technology Assessment and Comparative Effectiveness in Sweden

    Jun 1, 2010, 00:00

  • Quantifying Women's Stated Benefit–Risk Trade-Off Preferences for IBS Treatment Outcomes

    Jun 1, 2010, 00:00

  • Effects of Method of Translation of Patient-Reported Health Outcome Questionnaires- A Randomized Study of the Translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden

    Jun 1, 2010, 00:00

  • Impact of Waist Circumference Difference on Health-Care Cost among Overweight and Obese Subjects- The PROCEED Cohort

    Jun 1, 2010, 00:00

  • Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population

    Jun 1, 2010, 00:00

  • Factors Influencing Cost-Related Nonadherence to Medication in Older Adults- A Conceptually Based Approach

    Jun 1, 2010, 00:00

  • Dimensionality and Summary Measures of the SF-36 v1.6- Comparison of Scale- and Item-Based Approach Across ECRHS II Adults Population

    Jun 1, 2010, 00:00

  • Conditionally Funded Field Evaluations- PATHs Coverage with Evidence Development Program for Ontario

    Jun 1, 2010, 00:00

  • Response to- A Methodology for Successfully Producing Global Translations of Patient-Reported Outcomes Measures for Use in Multiple Countries by Two et al.

    Jun 1, 2010, 00:00

  • Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population- Results from a French Panel Study

    Jun 1, 2010, 00:00

  • Editorial

    Jun 1, 2010, 00:00

  • The Effect Size in Uncertainty Analysis

    Jun 1, 2010, 00:00

  • Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries

    Jun 1, 2010, 00:00

  • Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

    Jun 1, 2010, 00:00

  • Modeling Complex Treatment Strategies- Construction and Validation of a Discrete Event Simulation Model for Glaucoma

    Jun 1, 2010, 00:00

  • Assessing Outcomes in Liver Disease Patients- Reliability and Validity of the Spanish Version of the Liver Disease Quality of Life Questionnaire (LDQOL 1.0)

    Jun 1, 2010, 00:00

  • The Suitability of Polycystic Ovary Syndrome-Specific Questionnaires for Measuring the Impact of PCOS on Quality of Life in Clinical Trials

    Jun 1, 2010, 00:00

  • Reflecting Heterogeneity in Patient Benefits- The Role of Subgroup Analysis with Comparative Effectiveness

    Jun 1, 2010, 00:00

  • Health Technology Assessment in the United Kingdom

    Jun 1, 2010, 00:00

  • Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis

    Jun 1, 2010, 00:00

  • Transferability of Model-Based Economic Evaluations- The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

    Jun 1, 2010, 00:00

  • Comparative Assessment for Medications and Devices- Apples and Oranges?

    Jun 1, 2010, 00:00

  • Response to the Letter from Ms. Tamzin Furtado

    Jun 1, 2010, 00:00

  • PSY25 COST-EFFECTIVENESS OF NONINVASIVE MAGNETIC RESONANCE DIRECT THROMBUS IMAGING AND ULTRASONOGRAPHY FOR DIAGNOSING DISTAL DEEP VEIN THROMBOSIS

    May 1, 2010, 00:00

  • PCN68 COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC)- THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL

    May 1, 2010, 00:00

  • PCN22 DO GAPS IN TREATMENT CONTINUATION OF DOCETAXEL AFFECT OVERALL SURVIVAL? - RESULTS FROM A US LOCAL COMMUNITY PRACTICE

    May 1, 2010, 00:00

  • PMH78 ANALYSIS OF ADOLESCENT PATIENTS WITH NON-DEPRESSIVE NEUROSES IN COMPARISON TO THE GENERAL INPATIENT GROUP

    May 1, 2010, 00:00

  • PMC17 A COMPARISON OF THE DISCRIMINTATIVE AND EVALUATIVE PROPERTIES OF THE SF-36 AND THE SF-6D INDEX

    May 1, 2010, 00:00

  • PMS8 HIGH-COST MEDICATIONS IN 10 COUNTRIES- A CROSS-SECTIONAL COMPARATIVE STUDY

    May 1, 2010, 00:00

  • ME2 THE EFFECT OF MEDICARE PART D PRESCRIPTION DRUG COVERAGE GAP ON MEDICATION ADHERENCE

    May 1, 2010, 00:00

  • PCN140 INFLUENCE OF HEALTH TECHNOLOGY ASSESSMENTS ON UTILIZATION OF BEVACIZUMAB IN EUROPE

    May 1, 2010, 00:00

  • PMH23 DEMOGRAPHIC AND CLINICAL PREDICTORS OF HIGH-DOSE PRESCRIPTION OF DULOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2010, 00:00

  • PCN84 COST EFFECTIVENESS ANALYSIS OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR AGENTS FOR TREATMENT REFRACTORY METASTATIC COLORECTAL CANCER

    May 1, 2010, 00:00

  • PCN15 STATIN USE AND THE RISK OF COLORECTAL CANCER- A POPULATION-BASED COHORT STUDY

    May 1, 2010, 00:00

  • PHP115 AN ECONOMIC EVALUATION OF FIBRIN SEALANTS USED DURING INCISIONAL HERNIA WITH DERMOLIPECTOMY PROCEDURES IN SPAIN

    May 1, 2010, 00:00

  • PRS29 SMOKING AND WORKPLACE CONSEQUENCES- EVALUATION IN FRANCE

    May 1, 2010, 00:00

  • PCN112 LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW FOR THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME RESEARCH STRATEGY FOR CANCER-RELATED ANEMIA

    May 1, 2010, 00:00

  • PSY59 USING PATIENT FOCUS GROUPS TO INFORM ECONOMIC MODELING- EXPERIENCE FROM A HEMOPHILIA PATIENT FOCUS GROUP

    May 1, 2010, 00:00

  • PCV48 COMMUNITY-BASED CARE FOR THE SPECIALIZED MANAGEMENT OF HEART FAILURE- A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    May 1, 2010, 00:00

  • PUK2 RETROSPECTIVE DATABASE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE UTILIZATION OF MEMBERS WITH STAGE 3 CHRONIC KIDNEY DISEASE WITH ANEMIA

    May 1, 2010, 00:00

  • PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

    May 1, 2010, 00:00

  • PRS16 ECONOMIC BURDEN OF EXACERBATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2010, 00:00
  • «
  • 141
  • 142
  • 143
  • 144 (current)
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • »